SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,322 | $2,239 | $23,904 | $60,876 |
| % Growth | -40.9% | -90.6% | -60.7% | – |
| Cost of Goods Sold | $4,793 | $3,745 | $3,292 | $1,654 |
| Gross Profit | -$3,470 | -$1,506 | $20,612 | $59,222 |
| % Margin | -262.4% | -67.3% | 86.2% | 97.3% |
| R&D Expenses | $30,165 | $16,515 | $36,439 | $57,184 |
| G&A Expenses | $0 | $23,799 | $16,383 | $17,086 |
| SG&A Expenses | $9,275 | $23,799 | $16,383 | $17,086 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$3,745 | -$3,292 | -$1,654 |
| Operating Expenses | $39,440 | $36,569 | $49,530 | $72,616 |
| Operating Income | -$42,911 | -$38,075 | -$28,918 | -$13,393 |
| % Margin | -3,244.9% | -1,700.5% | -121% | -22% |
| Other Income/Exp. Net | $8,805 | -$4,118 | $10,203 | -$3,751 |
| Pre-Tax Income | -$34,105 | -$42,194 | -$18,715 | -$17,145 |
| Tax Expense | $0 | $0 | $26 | $0 |
| Net Income | -$34,105 | -$42,194 | -$18,741 | -$17,145 |
| % Margin | -2,579% | -1,884.5% | -78.4% | -28.2% |
| EPS | -3.68 | -7.64 | -4.31 | -3.94 |
| % Growth | 51.8% | -77.3% | -9.4% | – |
| EPS Diluted | -3.68 | -7.64 | -4.31 | -6.3 |
| Weighted Avg Shares Out | 9,262 | 5,521 | 4,352 | 4,347 |
| Weighted Avg Shares Out Dil | 9,262 | 5,521 | 4,352 | 2,734 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,286 | $585 | $71 | $23 |
| Interest Expense | $318 | $315 | $302 | $294 |
| Depreciation & Amortization | $4,793 | $3,745 | $3,292 | $1,654 |
| EBITDA | -$28,994 | -$38,133 | -$15,122 | -$15,196 |
| % Margin | -2,192.5% | -1,703.1% | -63.3% | -25% |